Top

Published in:

01-05-2009 | Original Article

Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis

Authors: Arzu Seven, Savaş Güzel, Mahmure Aslan, Vedat Hamuryudan

Published in: Rheumatology International | Issue 7/2009

Abstract

This study was designed to investigate the serum and synovial fluid leptin levels, and inflammatory markers in rheumatoid arthritis (RA) patients. Serum and synovial fluid leptin levels were significantly higher (P > 0.05) in RA patients than control group; RA patients with moderate disease activity (DAS < 2.7) having significantly higher leptin levels (P > 0.05) than those with low disease activity (DAS < 2.7). Leukocytes and erythrocyte sedimentation rate (ESR) were found to be significantly higher in moderate disease activity RA group compared to low activity group (P > 0.05, P < 0.001, respectively). Serum leptin level is found to be independent of age and inflammatory markers. ESR is positively correlated with DAS activity and CRP values. Our finding of no correlation between leptin and BMI shows that regulation of leptinemia is complex, and leptin levels cannot be used to assess RA activity.

Palmer G, Gabay C (2003) A role for leptin in rheumatic diseases? Ann Rheum Dis 62(10):913–915. doi:10.1136/ard.62.10.913 PubMedCrossRef

Otero M, Lago R, Lago F et al (2005) Leptin, from fat to inflammation: old questions and new insights. FEBS Lett 579(2):295–301. doi:10.1016/j.febslet.2004.11.024 PubMedCrossRef

Auwerx J, Staels B (1998) Leptin. Lancet 351(9104):737–742. doi:10.1016/S0140-6736(97)06348-4 PubMedCrossRef

Faggioni R, Feingold KR, Grunfeld C (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 15(14):2565–2571. doi:10.1096/fj.01-0431rev PubMedCrossRef

Otero M, Lago R, Gomez R et al (2006) Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford) 45(8):944–950. doi:10.1093/rheumatology/kel157 CrossRef

Loffreda S, Yang SQ, Lin HZ et al (1998) Leptin regulates proinflammatory immune responses. FASEB J 12(1):57–65PubMed

Busso N, So A, Chobaz-Péclat V et al (2002) Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis. J Immunol 168(2):875–882PubMed

Arnett FC, Edworthy SM, Bloch DA (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324. doi:10.1002/art.1780310302 PubMedCrossRef

van der Heijde DM, van’t Hof M, van Riel PL, van de Putte LB (1993) Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20(3):579–581PubMed

10.

Lee SW, Park MC, Park YB, Lee SK (2007) Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int 27(6):537–540. doi:10.1007/s00296-006-0253-x PubMedCrossRef

11.

Otero M, Lago R, Gomez R et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65(9):1198–1201. doi:10.1136/ard.2005.046540 PubMedCrossRef

12.

Bokarewa M, Bokarew D, Hultgren O, Tarkowski A (2003) Leptin consumption in the inflamed joints of patients with rheumatoid arthritis. Ann Rheum Dis 62(10):952–956. doi:10.1136/ard.62.10.952 PubMedCrossRef

13.

Wisołwska M, Rok M, Jaszczyk B, Stepień K, Cicha M (2007) Serum leptin in rheumatoid arthritis. Rheumatol Int 27(10):947–954. doi:10.1007/s00296-007-0335-4

14.

Gunaydin R, Kaya T, Atay A, Olmez N, Hur A, Koseoglu M (2006) Serum leptin levels in rheumatoid arthritis and relationship with disease activity. South Med J 99(10):1078–1083PubMed

15.

Anders HJ, Rihl M, Heufelder A, Loch O, Schattenkirchner M (1999) Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. Metabolism 48(6):745–748. doi:10.1016/S0026-0495(99)90174-9 PubMedCrossRef

16.

Hizmetli S, Kisa M, Gokalp N, Bakici MZ (2007) Are plasma and synovial fluid leptin levels correlated with disease activity in rheumatoid arthritis? Rheumatol Int 27(4):335–338. doi:10.1007/s00296-006-0264-7 PubMedCrossRef

17.

Sarraf P, Frederich RC, Turner EM et al (1997) Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 185(1):171–175. doi:10.1084/jem.185.1.171 PubMedCrossRef

18.

Nishiya K, Nishiyama M, Chang A, Shinto A, Hashimoto K (2002) Serum leptin levels in patients with rheumatoid arthritis are correlated with body mass index. Rinsho Byori 50(5):524–527PubMed

19.

Grunfeld C, Pang M, Shigenaga JK et al (1996) Serum leptin levels in the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 81(12):4342–4346. doi:10.1210/jc.81.12.4342 PubMedCrossRef

20.

Popa C, Netea MG, Radstake TR, van Riel PL, Barrera P, van der Meer JW (2005) Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. Ann Rheum Dis 64(8):1195–1198. doi:10.1136/ard.2004.032243 PubMedCrossRef

21.

Tokarczyk-Knapik A, Nowicki M, Wyroślak J (2002) The relation between plasma leptin concentration and body fat mass in patients with rheumatoid arthritis. Pol Arch Med Wewn 108(2):761–767PubMed

Title: Serum and synovial fluid leptin levels and markers of inflammation in rheumatoid arthritis
Authors: Arzu Seven
Savaş Güzel
Mahmure Aslan
Vedat Hamuryudan
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 7/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0764-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2009

Antiphospholipid antibody, head-shaking and ataxia: an evidence of non-vascular neurotoxicity and successful treatment by plasmapheresis

The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients

A proposed model for effective collaboration between rheumatologists and clinical pathologists for the diagnosis of autoimmune rheumatic diseases

Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients

Lymphocyte counts in patients with ANCA-associated vasculitis

Chronic recurrent multifocal osteomyelitis in a patient with selective immunoglobulin M deficiency

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials